Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.  The company is collaborating with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals Inc. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to the standard of care. “While disappointed that the Phase 2 ADX71149 epilepsy study did not meet the primary endpoint, we are still ...